Pharmacogenomic approaches that may guide preeclampsia therapy
| Contribuinte(s) |
Universidade Estadual Paulista (UNESP) |
|---|---|
| Data(s) |
27/05/2014
27/05/2014
01/04/2013
|
| Formato |
591-593 |
| Identificador |
http://dx.doi.org/10.2217/pgs.13.23 Pharmacogenomics, v. 14, n. 6, p. 591-593, 2013. 1462-2416 1744-8042 http://hdl.handle.net/11449/75024 10.2217/pgs.13.23 WOS:000317405300001 2-s2.0-84875973410 |
| Idioma(s) |
eng |
| Relação |
Pharmacogenomics |
| Direitos |
closedAccess |
| Palavras-Chave | #antihypertensive therapy #epigenetics #epistasis #pharmacogenomics #preeclampsia #atorvastatin #endoglin #hydralazine #labetalol #methyldopa #nifedipine #nitric oxide #vasculotropin receptor 1 #CACNA1A gene #CYP3A5 gene #disease marker #DNA polymorphism #eNOS gene #FLT 1 gene #gene #human #MMP9 gene #personalized medicine #review #treatment outcome #VEGF gene #VEGFR 1 gene #VEGFR 2 gene |
| Tipo |
info:eu-repo/semantics/article |
